Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tonghua Dongbao Pharmaceutical Co has the GF Score of 83, which implies that the company
might have
Good outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Tonghua Dongbao Pharmaceutical Co
might have
Good outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Tonghua Dongbao Pharmaceutical Co (SHSE:600867) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Tonghua Dongbao Pharmaceutical Co GF Score Related Terms
SHSE:600867 vs ZTS, UTHR: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tonghua Dongbao Pharmaceutical Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tonghua Dongbao Pharmaceutical Co GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tonghua Dongbao Pharmaceutical Co's GF Score distribution charts can be found below:
* The bar in red indicates where Tonghua Dongbao Pharmaceutical Co's GF Score falls into.
Tonghua Dongbao Pharmaceutical Co (SHSE:600867) has a GF Score of 83 as of Jul. 22, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Tonghua Dongbao Pharmaceutical Co and its competitors. This is near median its historical median of 87.00. Over the past decade, Tonghua Dongbao Pharmaceutical Co's GF Score has ranged from 65.00 to 100.00.
Is Tonghua Dongbao Pharmaceutical Co's GF Score too high?
Tonghua Dongbao Pharmaceutical Co's current GF Score of 83 is near median its 10-year median of 87.00. Over the past 10 years, this metric has ranged from a low of 65.00 to a high of 100.00. Overall, Tonghua Dongbao Pharmaceutical Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tonghua Dongbao Pharmaceutical Co's GF Score compare to ZTS and UTHR?
Tonghua Dongbao Pharmaceutical Co's GF Score of 83 can be compared against companies in the Drug Manufacturers industry. Historically, Tonghua Dongbao Pharmaceutical Co's own GF Score has ranged from 65.00 to 100.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Tonghua Dongbao Pharmaceutical Co and its competitors. Tonghua Dongbao Pharmaceutical Co's current GF Score is 83, which is near median its own 10-year median of 87.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonghua Dongbao Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Tonghua Dongbao Pharmaceutical Co (SHSE:600867) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.28, compared to a current price of ¥8.20 — trading 20.2% below its estimated fair value. The current GF Score is 83, which is near median its 10-year median of 87.00. Tonghua Dongbao Pharmaceutical Co's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Tonghua Dongbao Pharmaceutical Co (SHSE:600867), the current GF Score is 83 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tonghua Dongbao Pharmaceutical Co (SHSE:600867) Overvalued in 2026?
Based on GuruFocus' analysis, Tonghua Dongbao Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.20 is trading 20.2% below its estimated GF Value™ of ¥10.28.
GuruFocus considers Tonghua Dongbao Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600867:
GF Score: 83 (near median its 10-year median of 87.00)
GF Value™: ¥10.28 vs. price of ¥8.20 (20.2% below fair value)
No single metric tells the full story. See the SHSE:600867 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tonghua Dongbao Pharmaceutical Co Business Description
Tonghua Dongbao Pharmaceutical Co Ltd is a China-based firm. Its engaged in the production and distribution of pharmaceutical products. Its products include human insulin injection, Heart and brain capsule, Vitamin e soft capsule, and Oral detoxification products.
83GF Score
Get the complete analysis for SHSE:600867
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600867 has been successfully added to your 
